Ultralife (ULBI) Q2 2026 Earnings Call Transcript

Ultralife reported Q2 2026 revenue of $47.9M (-1.3% YoY) and GAAP EPS of $0.15 (vs. $0.05), alongside a record $117.5M backlog (+39% YoY). Gross margin jumped to 28.9% (+500 bps), boosted by a $1.1M IEEPA tariff refund contributing +230 bps, while adjusted EBITDA rose to $6.1M (12.8% of sales) from $4.1M. Management highlighted July order pull-through to nearly $130M backlog and expects 30% growth in cell consumption over the next year, with annual Battery & Energy gross margin savings of ~$600k–$800k.

Analysis

ULBI’s setup is less about the headline backlog number and more about whether management is finally converting a long-dated design pipeline into repeatable shipment cadence. The near-term upside is real because the company is showing operating leverage in the battery segment while the communications side is starting to benefit from higher-margin mix; if that persists for 1-2 quarters, the stock can re-rate even without a step-change in revenue. The key mechanism is margin normalization plus backlog conversion, not top-line scale.

The market may be underestimating the second-order benefit of vertical integration: if Electrochem cells are pulled deeper into finished packs, ULBI can capture more content per platform and reduce dependence on outside suppliers, which should improve both gross margin stability and qualification stickiness over 6-18 months. That said, the communications opportunity is still programmatic and timing-sensitive; a few awards or pull-through orders can make quarterly growth look stronger than the underlying run rate. In small caps like this, the risk is that backlog is over-read as recurring revenue when some of it may be lumpy defense timing.

Contrarian risk: a meaningful chunk of the margin improvement appears non-recurring or operationally specific, so the cleanest falsifier is whether ex-tariff-refund gross margin holds near the mid-20s while opex stays controlled. If Q3/Q4 shipments do not accelerate or if the $7M+ conformal backlog slips, the valuation support from "record backlog" fades quickly. The better read-through is to defense-electronics suppliers and rugged compute ecosystems: ULBI is trying to become a content vendor inside larger primes, which creates upside, but also leaves it vulnerable to being spec’d out if larger integrators bundle similar capability at scale.

Key Decisions for Investors

• Long ULBI on pullbacks over the next 2-6 weeks; thesis is backlog conversion + margin sustainment, with a 12-18% upside case if Q3 shows follow-through and a tight stop if gross margin ex-tariff falls back below ~25%
• Use a ULBI call spread into the next earnings window rather than common stock if liquidity allows; the asymmetry is highest into the Q4 product shipment catalyst, but the position should be sized for small-cap gap risk
• Watchlist alert, not a trade yet: HPE as a minor indirect beneficiary of tactical server pull-through, but the revenue impact looks too small to justify a standalone position until ULBI discloses meaningful design-win volume
• Avoid chasing the move if the stock gaps up sharply on the print; the non-recurring refund and timing-driven Communications Systems revenue make this a better buy-on-weakness setup than a momentum chase
• Falsifier: if backlog remains above $120M but Q3 revenue and gross margin do not inflect, treat the backlog as optically strong but economically low-conviction and reduce/exit